B. Yi

Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes

G. Herman, A. Bergman, B. Yi, 2006, Current medical research and opinion.

Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson’s Disease: A Systematic Review and Network Meta-Analysis

B. Yi, J. Cooper, R. Refoios Camejo, 2019, Advances in Therapy.

PIII‐60

W. Zeng, W. Smith, G. Herman, 2006 .

Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects.

J. Paolini, A. Bergman, B. Yi, 2006, International journal of clinical pharmacology and therapeutics.

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double‐blind, placebo‐controlled studies with single oral doses

W. Zeng, G. Herman, A. Bergman, 2005, Clinical pharmacology and therapeutics.

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

J. Holst, W. Zeng, C. Deacon, 2006, The Journal of clinical endocrinology and metabolism.

Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.

W. Zeng, G. Herman, A. Bergman, 2011, British journal of clinical pharmacology.

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

W. Zeng, G. Herman, A. Bergman, 2006, Clinical therapeutics.

An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation.

B. Yi, S. Hoffman, R. Marquis, 2010, Bone.